ROIVANT SCIENCES LTD. Deferred Revenue
ROIVANT SCIENCES LTD. (ROIV) had Deferred Revenue of $3.05 million as of 2025-12-31, per its 10-Q filed 2026-02-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-02-06
- 2025-12-31: Deferred Revenue, Current $3.05M.
- 2025-03-31: Deferred Revenue, Current $1.17M.
- 2024-12-31: Deferred Revenue, Current $3.04M.
- 2024-09-30: Deferred Revenue, Current $3.41M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2025-12-31 | $3.05M 10-Q · filed 2026-02-06 |
| 2025-03-31 | $1.17M 10-Q · filed 2026-02-06 |
| 2024-12-31 | $3.04M 10-Q · filed 2025-02-10 |
| 2024-09-30 | $3.41M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $2.66M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $4.17M 10-K · filed 2025-05-29 |
| 2023-12-31 | $4.70M 10-Q · filed 2024-02-13 |
| 2023-09-30 | $5.80M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $10.57M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $12.44M 10-K · filed 2024-05-30 |
| 2022-12-31 | $7.80M 10-Q · filed 2023-02-13 |
| 2022-09-30 | $8.37M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $9.01M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $10.15M 10-K · filed 2023-06-28 |
| 2021-03-31 | $5.92M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |